Overview

An Open Label Trial of Afatinib (Giotrif) in Treatment-naive (1st Line) or Chemotherapy Pre-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s)

Status:
Active, not recruiting

Trial end date:
2022-07-31

Target enrollment:

Participant gender:

Summary

To evaluate the safety and tolerability of afatinib (Giotrif) in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR mutation(s) and have never been treated with an EGFR-TKI

Phase:

Phase 3

Details

Lead Sponsor:

Boehringer Ingelheim

Treatments:

Afatinib